Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01494662
Title HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

Her2-receptor positive breast cancer

Therapies

Capecitabine + Neratinib

Neratinib

Age Groups: adult
Covered Countries USA


No variant requirements are available.